BRAF V600E mutation positive – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 16 Jun 2026 04:02:18 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png BRAF V600E mutation positive – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of encorafenib and cetuximab treatment for patients with BRAF V600E-mutant metastatic colorectal cancer who previously responded to BRAF inhibitor therapy https://clinicaltrials.eu/trial/study-of-encorafenib-and-cetuximab-treatment-for-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer-who-previously-responded-to-braf-inhibitor-therapy/ Wed, 29 Apr 2026 15:07:20 +0000 https://clinicaltrials.eu/trial/study-of-encorafenib-and-cetuximab-treatment-for-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer-who-previously-responded-to-braf-inhibitor-therapy/ This study focuses on patients with metastatic colorectal cancer who have a specific genetic change called BRAF V600E mutation. These patients have previously received and responded to treatment that included a BRAF inhibitor. The study will test a combination of two medications: encorafenib (taken by mouth) and cetuximab (given through a vein) as a retreatment option.

The purpose of this research is to determine how well this combination therapy works when given again to patients who have previously benefited from similar treatment but whose cancer has since progressed. The study will measure how long patients remain without their cancer getting worse, particularly during the first four months of treatment.

During this single-group study, all participants will receive both medications. The treatment can continue for up to 36 months, depending on how well it works and how well it is tolerated. Throughout the study, doctors will monitor patients’ health through regular medical examinations and tests to check for any side effects and to see how the treatment is working.

]]> Study on the Effectiveness and Safety of Plixorafenib (FORE8394) for Patients with Cancer Having BRAF Alterations https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-plixorafenib-fore8394-for-patients-with-cancer-having-braf-alterations/ Wed, 29 Apr 2026 15:00:20 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-plixorafenib-fore8394-for-patients-with-cancer-having-braf-alterations/ This clinical trial is focused on studying certain types of cancer that have changes in a gene called BRAF. These changes are known as BRAF alterations. The trial is testing a new treatment called Plixorafenib, also known by its code name FORE8394. This treatment is designed to target and inhibit specific changes in the BRAF gene, which are found in some cancers. The purpose of the study is to evaluate how effective and safe Plixorafenib is for patients with these specific genetic changes in their cancer.

The study involves two main groups of participants. The first group includes individuals with advanced or spreading solid tumors or certain brain tumors that have a specific type of BRAF change called a BRAF fusion. The second group includes individuals with a type of brain tumor known as high-grade glioma that has a different BRAF change called the BRAF V600E mutation. Participants in the study will receive the treatment in the form of tablets taken by mouth. The study will last for a period of up to 120 days, during which the effects of the treatment will be closely monitored.

Throughout the study, participants will be assessed to determine how well the treatment is working and to monitor any side effects. The study aims to gather information on the treatment’s impact on the cancer and its safety profile. This information will help researchers understand the potential benefits and risks of using Plixorafenib for treating cancers with BRAF alterations.

]]> Study of Encorafenib and Binimetinib for Patients with BRAFV600E-Mutant Metastatic Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-of-encorafenib-and-binimetinib-for-patients-with-brafv600e-mutant-metastatic-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:58:26 +0000 https://clinicaltrials.eu/trial/study-of-encorafenib-and-binimetinib-for-patients-with-brafv600e-mutant-metastatic-non-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as BRAFV600E-mutant metastatic Non-small Cell Lung Cancer. The study is testing a combination of two medications: Encorafenib, which is a BRAF inhibitor, and Binimetinib, a MEK inhibitor. These medications are being used together to see how effective they are in treating this specific type of lung cancer.

The purpose of the study is to evaluate how well the combination of encorafenib and binimetinib works in patients with this type of lung cancer. Participants in the study will take these medications orally, meaning they will swallow them in the form of capsules and tablets. The study will last for a period of up to 60 days, during which the effects of the treatment will be closely monitored.

Throughout the study, researchers will assess the response of the cancer to the treatment, looking for any signs of improvement or progression. The study aims to provide valuable information on the potential benefits of using these medications together for patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer.

]]>